Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAVINCY trial
2024-517846-32-00Phase 3Completed
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fosaprepitant and aprepitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoint: Complete response in delayed phase. Started Nov 2024; status: completed.
02
Drugs
fosaprepitantaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2024-517846-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517846-32-00.